Bioconjugates
Through our advanced expertise, Lonza entered the bioconjugates market in 2006 with a focus on ADCs. Our portfolio has further extended beyond cytotoxic payload Bioconjugates to include novel non-cytotoxic bioconjugates. We are your integrated, end-to-end CDMO partner to develop and manufacture Bioconjugates.